DEED OF VARIATION
between
COMMONWEALTH OF AUSTRALIA acting through and represented by the National
Blood Authority, a Commonwealth agency established under the National Blood Authority
Act 2003 (NBA)
and
AUSTRALIAN RED CROSS SOCIETY (ARCS) a body corporate established by Royal
Charter dated 28 June 1941, acting through that part of its operations known as the
Australian Red Cross Blood Service (Blood Service)
Recitals
A.
The Parties entered into a Deed of Agreement (Principal Deed) dated
21 August 2006.
B.
Clause 17.1 provides that no variation to the Principal Deed will be binding unless
agreed in writing between the Parties.
C.
The Parties varied the Principal Deed on 30 June 2009 and 30 June 2010, 30 June
2011 and 15 December 2011.
D.
The Parties now wish to vary the Principal Deed (as varied to date) in accordance
with this Deed of Variation.
Operative Provisions
Part A: Interpretation and operation of this Deed of Variation
1.
This Deed of Variation operates from 1 July 2012, in respect of the 2012-2013
financial year, until 30 June 2013.
2.
The parties may further extend this Deed of Variation from 1 July 2013 until 31
December 2013 by agreement in writing by way of an exchange of letters signed
by both parties before 30 June 2013. If the Deed of Variation is so extended, the
parties may further extend this Deed of Variation from 1 January 2014 until 30
June 2014 by agreement in writing by way of an exchange of letters signed by
both parties before 31 December 2013.
3.
Unless the contrary intention appears, in and for the purposes of this Deed of
Variation:
3.1
words or phrases in the Principal Deed have the same defined meaning,
except that the term ‘the Blood Service’ rather than the term ‘ARCBS’ is
used to refer to the Australian Red Cross Blood Service;
3.2
the rules of interpretation set out in Schedule 2 of the Principal Deed
apply;
3.3
‘Output Based Funding Model’ means the document at Annex 1 to this
Deed of Variation;
Blood Service – NBA Deed of Variation
1
3.4
the phrase ‘Product Price’ or ‘PP’ in the Output Based Funding Model or
Part C of this Deed of Variation will be taken to be within the meaning of
the phrase ‘Product Unit Payment’ or ‘PUP’ in the Principal Deed; and
3.5
the phrase ‘Capital Funding Payment’ in the Output Based Funding
Model or Part C of this Deed of Variation will be taken to be within the
meaning of the phrase ‘Capital Payment’ in the Principal Deed.
4.
A reference in the Principal Deed to Schedule 6 of the Principal Deed will be
taken to include a reference to Part C of this Deed of Variation and to the Output
Based Funding Model.
5.
The laws of the Australian Capital Territory apply to this Deed of Variation.
Part B
Extension and amendment of the Principal Deed
6.
In clause S1-2.1 of Schedule 1 of the Principal Deed:
6.1 replace ‘30 June 2012’ with ’30 June 2013’,
6.2 if the parties extend this Deed of Variation in accordance with clause 2, then
replace ’30 June 2013’ with ’31 December 2013’;
6.3 if the parties further extend this Deed of Variation to 30 June 2014 in
accordance with clause 2, then replace ’31 December 2013’ with ‘30 June
2014’.
7.
In relation to the operation of clauses 29.10 to 29.12 and Schedule 6 Items 7.1 to
7.5 of the Principal Deed dealing with Change Program Funding Pool Payments:
7.1
the Blood Service may continue to invoice, hold and use; and
7.2
NBA may continue to pay in response to a correctly rendered invoice,
Change Program Funding Pool Payments after 30 June 2010, in accordance with
the Principal Deed, to the extent that such Payments are in respect of a specific
initiative agreed by the Parties under Schedule 6 Items 7.2 and 7.3 on or before
30 June 2010.
Part C
Determination of Payments for 2012-13 financial year until 30 June 2013
8.
The following provisions in the Principal Deed do not operate in respect of the
2012-2013 financial year up to 30 June 2013:
9.
8.1
Schedule 6 Part A (Basis for Payments) Items 2, 3, 4, 5 and 6; and
8.2
Schedule 6 Part B (Invoicing and Payment) Items 11.1, 11.2, 11.4 and
11.6.
In giving effect to clause 8 of this Deed of Variation, the Parties have:
9.1
agreed the Product Price for each Product (including the Tier 1, Tier 2
and Non Tier Product Prices) to be applied for 2012-13 as specified in
Annex 2 (GST exclusive) ;
9.2
agreed the following amounts to be applied from 1 July 2012:
Blood Service – NBA Deed of Variation
2
10.
9.2.1
the amount of the Capital Funding Payments for 2012-13 is
$48,664,698 (GST exclusive) and has been included in the
Product Prices specified in Annex 2;
9.2.2
the amount of the Research and Development Payments for
2012-13 including capital is $8,092,159 (GST exclusive) to be
paid as an Other Payment under the Principal Deed;
9.2.3
the amount of, and conditions applying to, Payments in respect
of the Blood Service NSW and ACT Principal Site for 2012-13
is $9,201,085 (GST exclusive) to be paid as an Other Payment
under the Principal Deed;
9.2.4
the amount of, and conditions applying to, Payments in respect
of the Blood Service VIC and TAS Principal Site for 2012-13 is
$4,619,999 (GST exclusive) to be paid as an Other Payment
under the Principal Deed;
9.3
agreed to negotiate the principles relating to Product substitution under
Item 4.1 of the Output Based Funding Model with a view to agreeing
those principles by 30 June 2013; and
9.4
agreed to comply with obligations under the Principal Deed in relation to
Payments in accordance with:
9.4.1
the elements agreed under clauses 9.1, 9.2 and 9.3 of this
Deed of Variation;
9.4.2
the Output Based Funding Model; and
9.4.3
this Deed of Variation.
The Parties acknowledge and agree that:
10.1
notwithstanding that this Deed of Variation extends the Principal Deed
until at least 30 June 2013, the 2012-13 financial year is intended to
operate as the final year of a three year planning and funding cycle as
contemplated in the Output Based Funding Model;
10.2
despite Items 3.1 and 3.2 of the Output Based Funding Model, for the
2012-13 financial year the basis for planning of Product volumes
between the Parties must be Annual Supply Estimates in accordance
with Schedule 3 Part L of the Principal Deed;
10.3
despite Item 4.1 of the Output Based Funding Model, for the 2012-13
financial year, requirements in relation to the list of Products, frequency
of deliveries and inventory levels must be determined in accordance
with Schedule 3 of the Principal Deed;
10.4
clause 25 of the Principal Deed will apply to any activities of the Blood
Service referred to in Item 4.2 of the Output Based Funding Model;
10.5
Items 168 and 174 to 178 of Schedule 4 Table B of the Principal Deed
(as varied to date) are deleted;
Blood Service – NBA Deed of Variation
3
10.6
Items 160 to 163, 165, 167, 182, 184 and 192 of Schedule 4 Table B of
the Principal Deed (as varied to date) are amended as set out in Annex
3 to this Deed of Variation; and
10.7
other than the cash advances provided for in Item 6.1 of the Output
Based Funding Model, invoicing and payment must be in arrears in
accordance with Item 5.2 of the Output Based Funding Model and,
except to the extent of any inconsistency with Items 5.2 and 6.1 of the
Output Based Funding Model, in accordance with clauses 16.8 to 16.12
of Schedule 11 of the Principal Deed.
Part D
Treatment of financial outcome of 2011-12 financial year
11.
Items 16.4.1 to 16.4.3 of Schedule 11 of the Principal Deed do not operate in
respect of the 2011-12 financial year.
12.
Within 40 Business Days after the end of the 2011-12 financial year, the Parties
must undertake and agree a reconciliation of total actual costs incurred by the
Blood Service for the financial year (‘total actual costs’) against the total amount
of Payments made in respect of that financial year (‘total Payments’).
13.
If the reconciliation referred to in clause 12 of this Deed of Variation identifies a
deficit of total Payments against total actual costs, the Parties must agree any
appropriate treatment of the deficit in accordance with Item 6.2 of the Output
Based Funding Model.
Part E
Application of government policy
Records
Insert new clause 35.3:
35.3
This clause 35 applies for the Term and for a period of seven years
from the termination or expiry of this Deed.
Insert new clause 35.4:
35.4
The Blood Service must bear its own costs of complying with this clause
35.
Audit
Insert new clause 37.12:
37.12
The Blood Service agrees to ensure that any new Subcontract
entered into for the purposes of the Deed contains an equivalent
clause granting the rights specified in clauses 36 and 37.
Privacy
Insert new Clauses 38.1.13 to 38.1.15:
38.1.13 to notify individuals whose personal information the Blood
Service holds, that complaints about acts or practices of the
Blood Service may be investigated by the Privacy
Blood Service – NBA Deed of Variation
4
Commissioner who has power to award compensation
against the Blood Service in appropriate circumstances;
38.1.14 not to use or disclose personal information or engage in an
act or practice that would breach section 16F (direct
marketing) of the Privacy Act, a National Privacy Principle
(NPP) (particularly NPPs 7 to10) or an Approved Privacy
Code (APC), where that section, NPP or APC is applicable
to the Blood Service, unless:
(a)
in the case of section 16F - the use or disclosure is
necessary, directly or indirectly, to discharge an
obligation under this Deed; or
(b)
in the case of an NPP or an APC - where the activity
or practice is engaged in for the purpose of
discharging, directly or indirectly, an obligation
under this Deed, and the activity or practice which is
authorised by this Deed is inconsistent with the NPP
or APC; and
38.1.15 to comply as far as practicable with any policy guidelines
laid down by the Commonwealth or issued by the Privacy
Commissioner from time to time relating to the handling of
personal information.
Insert new Clause 38.8:
38.8
The Blood Service agrees to ensure that any Subcontract entered
into for the purpose of fulfilling its obligations under this Deed
contains provisions to ensure that the Subcontractor has the same
awareness and obligations as the Blood Service has under this
clause 38, including the requirement in relation to Subcontracts.
Amend clause 38.1.10 to include the words ‘or possible breach’ after ‘material breach’
Blood Service – NBA Deed of Variation
5
Annex 1 – OBFM Principles
OUTPUT BASED FUNDING MODEL for 2010-11 to 2012-13
Key Principles
All Australian Governments have agreed to continue to meet the fair and reasonable costs of the management and operation of the Australian Red Cross Blood
Service (Blood Service), including necessary investments in capital infrastructure. This commitment is limited to the cost of products and services provided in
accordance with arrangements established under the National Blood Agreement and consistent with policy determined by governments.
Australian Governments also require adequate accountability and transparency in the application of funding provided to the Blood Service and that the Blood
Service appropriately manage its affairs and associated financial risks within the resources provided by governments.
This funding model is to be read in conjunction with the Deed of Agreement dated 21 August 2006 which takes precedence over this agreement if in conflict. The
existing indemnities provided to the Blood Service by the NBA continue to apply (Clause 57).
Component
Item
OBFM Principles
1. Product
Costing
1.1
Costs for products reflect the actual cost of production
o
o
Corporate overheads and indirect costs will be attributed to products and services as outlined in 2 below.
Costs may not necessarily reflect the scarcity and difficulty of obtaining particular products.
1.2
Payment for services reflects the actual cost of providing that service.
1.3
Non-Deed services will not be cross subsidised by Deed funds.
1.4
Transfusion Medicine Services (TMS) will be funded under the existing process for 2010-11. Funding for 2011-12 onwards will be on the
basis of a new 3 tiered funding model which may include; grant, fee for service and a Product Price (PP) component and will be adjusted
annually by indexation (net of efficiency dividend) and 10% Capital. The PP component will grow in line with activity. The grant and the
fee for service component will be adjusted for activity growth where justified and agreed by JBC.
Research and Development will be grant funded based on the 2009-10 budget and will be adjusted annually by indexation (net of
efficiency dividend) and 10% Capital. The grant will be indexed by the activity growth where justified and agreed by JBC.
Blood Service – NBA Deed of Variation
6
Component
Item
OBFM Principles
1.5
Product costs will be fixed in each financial year of the cycle and not changed, other than in response to a major change in government
policy, a regulatory change, or other extraordinary reason which has been agreed by governments. Any JBC approved extraordinary
items will be grant funded for at least the term of the funding cycle at which time the interim grant funding where appropriate will be
incorporated into the PP.
1.6
Product costs will be indexed annually at 4.1% which is net of a 1% efficiency dividend. All other grants and payments will also be
indexed at 4.1% annually. This net indexation factor is in accordance with advice from the Commonwealth Department of Finance and
Deregulation as stated in the Forward Estimates.
A higher indexation rate may be approved by governments on presentation of evidence that business critical costs have risen well in
excess of 4.1% and the additional costs could not be recovered by other savings.
1.7
Product costs will facilitate international comparison and benchmarking where relevant and practical.
1.8
For items not funded through grant payments, an annual Capital Funding Payment will be made based on 10% of total annual estimated
revenue. Grant items mentioned in 1.4 and 1.13 are excluded from this capital payment as capital payments for these items are
separately defined and provided for.
While this funding will be incorporated in the PP it may be cash flowed within the year in advance of the PP payments subject to cash
being available with the NBA.
At the beginning of the year the monthly cash flow is provided by the Blood service as part of the Annual Capital Plan. Capital advances
will be made quarterly in advance and reconciled/acquitted quarterly with the monthly PP invoices, contingent on cash being available. If
cash is not available then a monthly advance will be provided and reconciled/acquitted quarterly with the monthly PP invoices.
1.9
At the cost agreement stage, the overall cost to governments of the products and services in 2010-11 cannot increase on the funding that
would have been provided based on 2009-10 costs (other than Indexation net of efficiency dividend), activity increases based on the
agreed supply plan, other extraordinary items and changes in government/regulatory policy.
Blood Service – NBA Deed of Variation
7
Component
Item
OBFM Principles
1.10
The costs of the following products will be constructed to reflect a two tiered costing structure to ensure recovery of 100% of fixed costs
when 90% of supply has been delivered. They are
-
2b W hole blood red cells – leucodepleted
4b Clinical fresh frozen plasma
4d Apheresis Clinical FFP
3b W hole blood platelets – leucodepleted
3d Apheresis platelets – leucodepleted
The tier one base cost will be fully costed to reflect recovery of 100% of fixed costs at 90% of delivered supply. Deliveries after 90% of the
supply plan are costed at variable cost.
100% of the Annual Capital Funding Payment as defined in 1.8 will be added to tier one product costs and plasma for fractionation.
Variable Costs are:
All consumables;
5% of operating unit overhead less rent and rates; and
3% of collection centres salary and statutory on costs.
All other costs are Fixed costs.
2. Attribution
Rules
1.11
The Blood Service will be a participant in the policy development of prices paid by jurisdictions.
1.12
Governments will provide reasonable notice to the Blood Service of their intention to increase or reduce services that are funded on a
fixed grant basis. Governments may be required to fund reasonable increased or exit costs.
1.13
Victoria/Tasmania Principal Site (VTPS) and New South W ales/Act Principal Site (NAPS) net additional expenses (fit out, rent, outgoings
etc) are to be separately funded on a grant basis and not included in the PP.
2.1
For costing attribution the principal purpose of the Blood Service is to provide a fresh blood service. The collection of plasma for
fractionation for costing purposes, is a non principal activity, and so only bears direct operating unit costs and excludes corporate and
operating unit management overhead.
Blood Service – NBA Deed of Variation
8
Component
Item
OBFM Principles
This approach will assist in:
•
•
•
2.2
providing internationally comparable fresh blood costs; and
keeping plasma costs lower to support domestic collection and governments policy to promote national self sufficiency.
Product costing outcomes are aimed at minimising risk to Blood Service from changes in volume and product mix (i.e. minimise
cross subsidisation and use of subjective drivers) by using supportable cost allocation methodologies and tier pricing that means
fixed costs and capital payments are not put at risk.
Costs which cannot be directly associated with an individual product eg donor services, donor recruitment, collection and testing, are
allocated on a collection based driver.
Direct Operating Costs that are absorbed by all products are all direct operating unit costs of Production, Distribution, product
specific Testing, or Product Enhancements involved in the production and processing of the separate product.
Separate product costs will not be established for value added activities such as irradiated red blood cells unless the cost of the value
added activity is material for the Blood Service.
Direct Operating costs
Includes:
o
o
o
o
o
o
o
Donor Centre Costs
- Labour
- Consumables
- Donor Centre Overheads
Testing (including those provided by the NTS within the Deed)
Production
Marketing & related activities (Operating Units only)
Principal Site Overheads (where not separately funded)
Medical Services Direct Product and Collection Support
Distribution of fresh blood products and plasma for fractionation
But excludes:
o
Corporate Overheads ie
- Finance
- Human Resources
- Information Systems
Blood Service – NBA Deed of Variation
9
Component
Item
2.3
2.4
2.5
OBFM Principles
- Quality
- Corporate
- Corporate Strategy and Performance
o Medical Services Management and Support
o National Operations Management
o National Transplantation Service (Excluding Testing done for the blood supply)
o Research and Development
o Operations unit management overheads
o Distribution costs of non fresh products
Distribution costs will be allocated to products on the basis of units issued.
Distribution costs include
o Labour, Consumables and Overheads (other than Transport),
o Fresh, fractionated and recombinant product transport,
o Plasma to CSL (Transport)
Corporate and Operating Unit Management Overhead will be allocated to fresh products excluding plasma for fractionation. These
overheads will be a standard charge for every adult equivalent product unit issued to eliminate the financial risks to the Blood Service of
product substitution.
Fresh Product and Clinical Focus:
Plateletpheresis direct operating unit costs should be allocated to the platelets only, not to the plasma for fractionation derived through
this collection (100% primary product).
3. Volumes
4. Products
and Services
3.1
Rolling three year supply forecasts will be provided by the NBA and jointly reviewed on an annual basis
3.2
The three year supply estimates prior to the commencement of the three year funding cycle are used to set the fixed cost recovery levels
for those products that have tiered costing structure.
3.3
During the year both NBA and the Blood Service will work together to best inform up to date trends on supply and demand.
4.1
There will be an agreed National Service Standards. Refer to this document for issues relating to Product List, frequency of deliveries,
inventory levels and principles relating to product substitution.
Blood Service – NBA Deed of Variation
10
Component
5. Payment
Process
6. Risk Treatment of
Cash
Advance,
Surplus or
Loss
Item
OBFM Principles
4.2
The Blood Service may provide services outside the deed to jurisdictions or other organisations at a Fee for Service. These services must
be fully cost recovered and do not impact on the Blood Service ability to meet deed obligations.
5.1
Payment is made for those products that are ordered and issued, and within defined and agreed substitution rules.
Payment on products received is the optimum goal (which ensures formal receipt verification), with payment on product issued
acceptable until a system allows (ie an inventory and receipting system implemented).
5.2
Invoicing occurs at the end of the month and payment is on agreed terms of 10 business days from receipt of a correctly rendered invoice
based on issues to Approved Health Providers.
5.3
After the first year of the model, NBA and the Blood Service will review the model and the Blood Service financial performance to ensure
appropriateness and to inform the costs/model for the remainder of the funding cycle.
6.1
The NBA will provide a cash advance to cover the initial 55 days operation, excluding capital, to be reconciled at the end of each year.
o
6.2
The advance will be split into two advances made at the beginning of July (30 days) and August (25 Days) and reconciled/acquitted
annually with the monthly PP invoice.
The Blood Service can approach the NBA within each year should there be events that require additional funding such as extraordinary
circumstances and government regulatory or policy changes.
The Blood Service can also approach the NBA in the event of a material change (as defined below) from forecast to actual supply to
meet demand (and/or year on year forecast) if the Blood Service needs to recoup costs associated with responding to those changes and
the overall costing structure does not accommodate it. This Includes changes in product mix that cause changes in cost structure or
changes in product cost or value added costs.
Materiality for one year result where a loss incurred is equivalent to $1.5M
The triggering of this clause will be at the discretion of the Blood Service, and the funds available and the level of financial risk that they
are prepared to manage before they seek reimbursement.
6.3
The Blood Service will be expected to manage losses annually (subject to 6.2) and within the 3 year funding cycle subject to materiality.
Blood Service – NBA Deed of Variation
11
Component
Item
OBFM Principles
The Blood Service can approach the NBA at the conclusion of the 3 year funding cycle should a material loss (as defined below) be
evident and seek to be reimbursed for the deficit.
Note: In the event of a claim for loss at the end of the funding cycle, the Blood Service will be subject to a full disclosure audit. In this
event, and subject to no impropriety, governments agree to maintain their existing commitment to meet the fair and reasonable costs of
the Blood Service. As agreed by AHMC in July 2008 (refer to the introduction statement above).
Materiality for three year result where losses incurred is equivalent to, $4.5M.
The triggering of this clause will be at the discretion of the Blood Service, and the funds available; and the level of financial risk that they
are prepared to manage before they seek reimbursement.
6.4
-
The Blood Service will be allowed to retain the 2009-10 operational efficiencies (surplus) to allow one off reinvestment in line with
government policy including;
o to comply with regulatory changes
o to improve the safety and security of the blood supply
o for strategies to achieve efficiencies in the blood service
o to further achieve national consistencies
o to reduce the product cost
o to provide for a management reserve (risk pool)
Subject to any resultant ongoing costs being absorbed within the agreed 2010-11 product prices.
6.5
-
Future Surplus - The Blood Service will be able to reinvest operational efficiencies (surplus) up to $5 million in any year to allow
reinvestment in line with government policy including;
o to comply with regulatory changes
o to improve the safety and security of the blood supply
o for strategies to achieve efficiencies in the blood service
o to further achieve national consistencies
o to reduce the product cost
o to provide for a management reserve (risk pool)
Subject to any resultant ongoing costs being absorbed.
It is intended that the first call on surplus funds will be any regulatory or government policy changes and new Business Cases approved
by JBC provided any on-going costs can be absorbed in existing funding.
Blood Service – NBA Deed of Variation
12
Component
Item
OBFM Principles
If the annual surplus is more than $5 million in any year then the use of the surplus over the $5 million will need to be agreed between the
Blood Service and the NBA.
7. Business
Cases
7.1
The Blood Service will have the opportunity to present business cases for projects/initiatives greater than $2m that cannot be funded
within price and services funding or surplus reinvestment, noting that this needs to align with government timeframes for new funding, i.e.
2 years out.
Acronyms:
NBA
Blood Service
JBC
TMS
PP
FFP
VTPS
NAPS
NTS
Blood Service – NBA Deed of Variation
National Blood Authority
Australian Red Cross Blood Service
Jurisdictional Blood Committee
Transfusion Medicine Services
Product Price
Fresh Frozen Plasma
Victoria/Tasmania Principal Site
New South W ales/Act Principal Site
National Transplantation Service
13
Annex 3 – Additions to Schedule 4 Table B of the Principal Deed
185
D
Quarterly CFO meeting
By 7 Aug 2012

By 31 Aug 2012


Quarterly CEO meeting
186
-
Year in Review 2011-12
Review Qtr 4 (April-June 2012)
187
C
Supply Plan Review for 2011-12
By 31 Aug 2012
188
C
Supply Trend Analysis for 2013-14
By 31 Aug 2012
Consultation on ASEs for 2013-14 (All
Product Groups) and consultation with
NBA on Supply Plan scenarios taking into
account proposed PP and business case
proposals, if any
1 Jul 2012 to
NBA to provide the Blood Service with
draft 2013-14 ASE
By 30 Sep 2012
Blood Service to submit Funding Guidance
Letter for 2013-14 to the NBA
31 Oct 2012 or after
date extended as
agreed
C
&
D

30 Sep 2012

189
C
End of year reconciliation of planned v.
actual supply for the purposes of clause 13
of the Deed of Variation
C
Consultation with NBA on business
planning scenarios for 2013-14 (including
operational planning, changes in business
practices and relevant policy and
regulatory changes) taking into account
proposed PPs and supply levels
G
D
190
191
192
193
1 Aug 2012
to 30 Sep 2012

1 Sep 2012
to 31 Oct 2012

Blood Service annual Research and
Development workshop for FY 2013-14
By 30 Sept 2012

Quarterly CFO meeting
By 7 Nov 2012
Blood Service – NBA Deed of Variation

14
2016-17
2015-16
2014-15
2013-14
Activity Date
2012-13
Activity
2011-12
Process
Financial Year that
Activity Relates to
Quarterly CEO Meeting
-
-
194
Review Qtr 1 (July-September
2012)
By 7 Dec 2012

195
C
NBA provides ASEs for FY 2013-14
By 31 Dec 2012

196
D
Agree PPs for FY 2013-14
By 31 Dec 2012

197
D
Quarterly CFO Meeting FY 2012-13
By 7 Feb 2013

By 14 Feb 2013

By 28 Feb 2013

Quarterly CEO Meeting FY 2012-13
-
-
198
Review Qtr 2 (October –
December 2012)
199
D
Six monthly reconciliation of planned
versus actual supply and conversion rates,
and adjustment if necessary for FY 201213
200
E
Blood Service to provide SCIP and ACP
FY 2013-14
By 30 April 2013

201
E
NBA approval of SCIP and ACP FY 201314
By 30 May 2013

202
D
Quarterly CFO Meeting FY 2012-13
By 7 May 2013

203
-
By 14 May 2013

Quarterly CEO Meeting FY 2012-13
-
Review Qtr 3 (January – March
2013)
Blood Service – NBA Deed of Variation
15
2016-17
2015-16
2014-15
2013-14
Activity Date
2012-13
Activity
2011-12
Process
Financial Year that
Activity Relates to
Executed as a Deed
SIGNED SEALED AND DELIVERED )
for and on behalf of the
)
COMMONWEALTH OF AUSTRALIA )
acting through the
)
NATIONAL BLOOD AUTHORITY
)
on:
)
)
)
Date
)
by:
)
)
)
Name of signatory
)
)
)
Position of signatory
)
in the presence of:
)
)
)
Name of witness
)
Signature
Signature of witness
Signed on behalf of the Australian Red Cross Society in accordance with its Rules:
Full Name of ARC Board Member or other
Authorised Representative
Signature
Position
Full Name of ARC Board Member or other
Authorised Representative
Signature
Position
Dated this
Blood Service – NBA Deed of Variation
day of
2012
16